Biogen Inc. BIIB shares are trading higher on Friday as the company is continuing its FDA review process for Leqembi Iqlik ...

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

The FDA has extended the review period for its supplemental biologics license application of Leqembi Iqlik by three months to Aug. 24.

Specifically, the FDA is delaying its verdict on once-weekly Leqembi Iqlik (lecanemab) as a starting dose for patients ...

Families, campaigners and clinicians are calling for more public money to be provided to pay for access to drugs which could ...

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License ...

For Roslyn Mannon, MD, a single patient experience inspired her path to nephrology.“The patient talked passionately about how ...

Several disease-modifying therapies for MS were associated with increased risks for urinary tract infections and urosepsis, ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Biogen, with a price target of $185.00. Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, ...

Full-year 2026 revenue guidance of $840 million to $870 million remains unchanged as management awaits a full quarter of post-supply-disruption data for Onepco. The company plans to initiate a Phase 1 ...

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen, with a price target of $196.00. According to TipRanks, Seigerman is a 4-star analyst with an average ...

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's ...